Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,146 public trials 2,034 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT05519085

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Local Institution - 0366 Los Alamitos, California, United States
  • Local Institution - 0272 San Diego, California, United States
  • Local Institution - 0273 West Hollywood, California, United States
  • Local Institution - 0381 Aurora, Colorado, United States
View all 266 locations
View Trial Details
Recruiting

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

NCT07003295

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Emory University Hospital Midtown Atlanta, Georgia, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • Emory Saint Joseph's Hospital Atlanta, Georgia, United States
View Trial Details
Recruiting

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

NCT05010005

Conditions
Disease Attributes, Hematologic Diseases, Hemic and Lymphatic Diseases, +22 more
Locations
  • University of Miami (Data Collection Only) Miami, Florida, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
View Trial Details
Recruiting

Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

NCT04915248

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • A.O. Spedali Civili di Brescia - Ematologia Brescia, Italy
  • Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia Milan, Italy
  • U.O. Ematologia AO di Padova Padova, Italy
  • Ematologia IRCCS Policlinico S. Matteo di Pavia Pavia, Italy
View all 18 locations
View Trial Details
Recruiting

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

NCT07225439

Conditions
B-cell Non Hodgkin Lymphoma, Chronic Disease, Chronic Lymphocytic Leukemia, +30 more
Locations
  • Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center Cleveland, Ohio, United States
  • Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute Cleveland, Ohio, United States
View Trial Details

Related conditions